Relationship Between Serum Interleukin-17 Level And Chemotherapy Effect In Patients With Multiple Myeloma

Objective:At present,there is still some controversy about the relationship between IL-17 and the occurrence and development of multiple myeloma.Therefore,this work is intended to study the relationship between IL-17 and the occurrence,development and efficacy of multiple myeloma.Methods:According to the inclusion criteria,68 patients with multiple myeloma admitted to the Central Hospital of Shaoyang from January 2016 to December 2018 were selected as the MM group(observation group).At the same time,29 random healthy subjects who did physical examination in the physical examination center of Shaoyang Central Hospital were selected as the control group.According to the D-S staging criteria of MM,the newly diagnosed MM patients were divided into stage I,II and III.According to the criteria for the efficacy of MM,by the different level of M protein in urine and serum and the level of free light chain in serum,the patients after chemotherapy were divided into 4 types,complete remission(CR),partial remission(PR),stable disease(SD),and progressive disease(PD),of which CR and PR were considered to be effective,and SD and PD were considered to be ineffective.ELISA technique was used to detect the serum IL-17 levels of the MM group and the control group,and the serum IL-17 levels of the patients in the MM group in various clinical stages.The results show that the average concentration of the serum IL-17 in the MM group was obviously higher than that of the control group.Results: The average concentration of the serum IL-17 in the MM group was(53.85±5.83)pg/ml,and that of the control group was(9.26±2.32)pg/ml.The average concentration of the serum IL-17 of the patients with stage II MM was(46.99±5.63)pg/ml,and the average concentration of the serum IL-17 in the patients with stage III MM was(55.79±4.23)pg/ml.The order of the serum IL-17 concentration in various clinical stages was stage III > II > the control group(P<0.05).The serum IL-17 concentration in the MM patients after effective chemotherapy was obviously lower than that before chemotherapy(P<0.05).The serum IL-17 level in stage II patients decreased from(45.886±3.985)pg/ml to(23.870±3.070)pg/ml;the serum IL-17 levels in patients with stage III decreased from(55.661±4.131)pg/ml to(26.595±3.404)pg/ml(P<0.05).Conclusions:This study suggests that IL-17 has a certain correlation with the occurrence,development and efficacy of multiple myeloma,.